Trials / Recruiting
RecruitingNCT06442436
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
A Study to Evaluate the Pharmacokinetics of Nemtabrutinib in Participants With Moderate Hepatic Impairment
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemtabrutinib (MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic impairment to that of healthy matched control participants and to evaluate the safety and tolerability of nemtabrutinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nemtabrutinib | 25 mg nemtabrutinib (1 x 5 mg and 1 x 20 mg tablets) administered orally as a single dose. |
Timeline
- Start date
- 2024-07-24
- Primary completion
- 2026-09-14
- Completion
- 2026-09-14
- First posted
- 2024-06-04
- Last updated
- 2026-02-11
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06442436. Inclusion in this directory is not an endorsement.